Biotech News
AN2 Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business and Scientific Highlights
Global Phase 2 study of oral epetraborole in polycythemia vera (PV) cleared to proceed in all planned jurisdictions; expect to initiate enrollment by year-end Enrollment ongoing in Phase 2 investigator-initiated trial of epetraborole for M. abscessus lung disease Advancing startup activities for
